Table 1.
Baseline characteristics of patients who received intraventricular rt-PA for IVHa
| Characteristic | Patients (n = 27) |
|---|---|
| Age, years | 59 (15.0) |
| Weight, kilograms | 82.8 (18.9) |
| Gender | |
| Male | 17 (63.0) |
| Female | 10 (37.0) |
| Ethnicity | |
| White/Caucasian | 16 (59.3) |
| African American | 7 (25.9) |
| Asian/Other | 4 (14.8) |
| Admission IVH category | |
| Primary IVH | 3 (11.1) |
| Secondary IVH (ICH or IPH) | 15 (55.6) |
| Secondary IVH (SAH)b | 9 (33.3) |
| Past medical historyc | |
| Hypertension | 22 (81.5) |
| Hyperlipidemia | 7 (25.9) |
| Previous TIA or stroke | 5 (18.5) |
| Medications prior to admission | |
| Anti-plateletd | 7 (25.9) |
| Warfarin | 2 (7.4) |
| Medications during admission | |
| Anti-plateletd | 8 (29.6) |
| Heparine | 12 (44.4) |
| Pro-coagulantf | 13 (48.2) |
ICH intracranial hemorrhage, IPH intraparenchymal hemorrhage, IVH intraventricular hemorrhage, SAH subarachnoid hemorrhage, TIA transient ischemic attack
a
Continuous data are presented as mean (one SD); categorical data as number of patients (percentage of sample)
b
Patients with secured aneurysms only
c
Risk factors for IVH
d
Aspirin, cilostazol, or clopidogrel
e
Heparin 5,000 units subcutaneous every 8 or 12 h; 1 patient received heparin during surgery
f
Aminocaproic acid, desmopressin, protamine sulfate, or recombinant factor VIIa